Hypersensitivity. Severe hypotension; shock (including cardiogenic shock); haemodynamically unstable heart failure after acute MI. Concomitant use w/ aliskiren-containing products in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m2). Obstruction of the outflow tract of the left ventricle. Severe hepatic impairment, biliary cirrhosis or cholestasis. Pregnancy (2nd & 3rd trimester).
Antagonized antihypertensive effects w/ NSAIDs. Reduced antihypertensive effects w/ sympathomimetics. May lead to elevation of serum K w/ K-sparing diuretics. May produce additive antihypertensive & antianginal effects w/ SL nitroglycerin, long-acting nitrates, β-blockers or other antianginal agents.
C09DB01 - valsartan and amlodipine ; Belongs to the class of angiotensin II receptor blockers (ARBs) and calcium channel blockers. Used in the treatment of cardiovascular disease.
Sign Out
